2014 ASCO GU Abstract#7 Driecer
Read More
San Francisco, CA -GU Cancers Symposium 2014: Robert Dreicer, MD discusses abstract #7 "Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial)" during the Oral Abstract Session A: Prostate Cancer at the 2014 Genitourinary Cancers Symposium here today, Thursday January 30, 2014. Over 3,100 physicians, researchers, patient advocates and healthcare professionals from over 50 countries attended the meeting which features the latest research on genitourinary cancer treatment and prevention. Photo by © ASCO/Todd Buchanan 2014 Technical Questions: todd@medmeetingimages.com
